12April

Gilead Sciences and Novo Nordisk announce intent to initiate a clinical collabor ... Read more

29March

Novo Nordisk invests DKK 650 million in upgrading and expanding production facil ... Read more

15April

Novo Nordisk A/S - Share repurchase programme ... Read more

08April

Novo Nordisk A/S - Share repurchase programme ... Read more

01April

Novo Nordisk A/S - Share repurchase programme ... Read more

25March

Novo Nordisk A/S - Share repurchase programme ... Read more

Contact Media

If you have any queries please feel free to contact Media Relations at Novo Nordisk headquarters or one of our global offices.

Contact Media Relations
 
Press material is intended for media.

 

Novo Nordisk Media


Gilead Sciences and Novo Nordisk announce intent to initiate a clinical collaboration in NASH  

12 April - Gilead Sciences and Novo Nordisk today announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH).

“We are very pleased about the potential to enter into this clinical collaboration with Gilead, which would combine Novo Nordisk’s semaglutide programme in NASH with Gilead’s clinical programmes to provide novel approaches for the treatment of the disease. By combining the leading molecular science and clinical expertise of our two companies within the rapidly expanding liver and metabolic diseases, we aim to develop innovative, new and effective combination therapies to help people with NASH,” said Mads Krogsgaard Thomsen, chief science officer and executive vice president of Novo Nordisk. 

Read the full announcement

 


Novo Nordisk files oral semaglutide for US regulatory approval of glycaemic control, as well as for CV risk reduction for oral semaglutide and Ozempic®

21 March - Novo Nordisk just announced the submission of two New Drug Applications (NDAs) to the US FDA for oral semaglutide, a once-daily glucagon-like peptide-1 (GLP-1) analogue in a tablet, as well as a supplemental NDA (sNDA) for once-weekly Ozempic® (semaglutide). Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk said, “Achieving glycaemic control and managing cardiovascular risk remains a challenge for many adults living with type 2 diabetes, we're excited about the regulatory filings of the first GLP-1 receptor agonist in a tablet, as we believe oral semaglutide has the potential to further improve the treatment of adults living with type 2 diabetes."

Read the full announcement

 


Towards a cure

When Becky Furuta was told her cycling career was over due to her diabetes, she defied doctors' orders to rise to the top of her profession.

Read the story about Beckypro-cyclist at Team Novo Nordisk, or listen to her story in the podcast

Subscribe to our perspectives 

 


Red Cross and Novo Nordisk in ground-breaking partnership to tackle chronic care in humanitarian crises

The International Committee of the Red Cross (ICRC), the Danish Red Cross (DRC) and Novo Nordisk have partnered to tackle the growing issue of chronic diseases that affect millions of people living in humanitarian crises around the world. Focus will be on ensuring efficient supply of low-cost human insulin in vials to Red Cross globally; support for ICRC’s and DRC’s health programmes; 2-3 projects to provide care to people with hypertension and diabetes in humanitarian crises to be conducted within three years.

Read CEO Lars Fruergaard's reflections and more about the partnership

 



Calendar

Financial results for first quarter of 2019
03MayDenmark


When Pâris was diagnosed with type 1 diabetes at the age of two, his mother Wendy began filming. She didn’t stop for 16 years. 

Watch the documentary, 'Safely in the Rainbow', on YouTube



Financial results 2019

3 May - first quarter 

9 August - first half 

1 November - third quarter 

 


Novo Nordisk in brief


Defeat NCDs

Zeana Massoud Said has type 1 diabetes. Zeana lives in Tanzania

The Danish Government and Novo Nordisk have announced grants of 3 and 5 million US dollars respectively to the Defeat-NCD Partnership. The aim is to raise 100 million dollars to fund mobilisation of knowledge, tools, capacities and finances to scale-up action to defeat NCDs in low-resource countries.

Read more details in the press release